Roundtable Discussion: Evaluating RNA Versus DNA in Gene Editing to Improve Safety Profiles & Align with Regulatory Expectations
- Examine how modality choice influences safety, efficacy, and scrutiny in clinical development
- Explore competitive advantages of RNA over DNA platforms across specific indications and cell types
- Align modality selection with CMC feasibility, delivery strategy, and reimbursement potential